Stayble Therapeutics presents the ongoing phase 2b study at the European Congress on Clinical Trials in Pain

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's ongoing Phase 2b study has been accepted for poster presentation at the 4th European Congress on Clinical Trials in Pain (SOPATE2022). The Congress will be held in Vienna, Austria, on December 7-8, 2022.

Stayble announces that the Company will present the ongoing Phase 2b study with STA363 at the European Congress on Clinical Trials in Pain in Vienna. The abstract is entitled Safety and Tolerability of STA363 in Patients with Degenerative Disc Disease and will be presented by Anders Lehmann, Chief Scientific Officer (CSO) of Stayble.

SOPATE2022 is a prestigious conference that will take place December 7-8, 2022, in Vienna, Austria. The congress focuses on clinical trials in pain and brings together researchers, clinicians, industry professionals and other experts in the field.

"We look forward presenting STA363 and its potential with leading international pain researchers. A conference like SOPATE2022 provides an important forum for exposure of STA363 to experts in clinical pain research and an opportunity to broaden our network of contacts for clinical trials,” says Anders Lehmann, CSO of Stayble.

For more information on SPOATE2022, please visit: https://sopate2022.com

The poster presentation is attached to this press release.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail ca@skmg.se